Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30155394 | 1.00 | ALDH1A1 (0.58) | ALDH1A1HIF1AVCAM1SMN1; SMN2CA1 | |
| SCHEMBL12868652 | 0.87 | ALDH1A1 (0.56) | ALDH1A1HIF1AVCAM1SMN1; SMN2CA1 | |
| SCHEMBL16654006 | 0.84 | ALDH1A1 (0.53) | ALDH1A1HIF1AVCAM1SMN1; SMN2CA1 | |
| SCHEMBL27734066 | 0.84 | ALDH1A1 (0.53) | ALDH1A1HIF1AVCAM1SMN1; SMN2CA1 | |
| SCHEMBL2340870 | 0.84 | EPAS1 (0.56) | ALDH1A1HIF1AVCAM1SMN1; SMN2CA1 | |
| SCHEMBL16950918 | 0.84 | ALDH1A1 (0.53) | ALDH1A1HIF1AVCAM1SMN1; SMN2CA1 | |
| SCHEMBL28597192 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HIF1AVCAM1SMN1; SMN2CA1 | |
| SCHEMBL257444 | 0.81 | VCAM1 (0.51) | ALDH1A1HIF1AVCAM1SMN1; SMN2CA1 | |
| SCHEMBL7981057 | 0.81 | GRM8 (0.52) | ALDH1A1HIF1AVCAM1SMN1; SMN2CA1 | |
| SCHEMBL10347723 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HIF1AVCAM1SMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090300-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090317-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090330-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4698544-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| EP-3500257-B1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025106383-A1 | PYRROLIDINYL DERIVATIVES USEFUL AS HCN1/HCN 2 MODULATORS | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025037871-A1 | TRICYCLIC COMPOUND AND USE THEREOF AS MAT2A INHIBITOR | 에스케이바이오팜 주식회사 | 2025-02-20 | — | — | WO | disclosed |
| WO-2024220946-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024220891-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2018035346-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2018-02-22 | — | — | WO | disclosed |
| US-8519149-B2 | Tricyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| WO-2012055995-A1 | TRICYCLIC COMPOUNDS AS MPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | US | disclosed |
| CN-101012174-A | Halogenating agents | MITSUI CHEMICALS INC (JP) | 2007-08-08 | — | — | CN | disclosed |
| CN-1202086-C | Halogenating agents | MITSUI CHEMICAL CO LTD (JP) | 2005-05-18 | — | — | CN | disclosed |
| US-4172831-A | CENTRAL NERVOUS SYSTEM | LILLY INDUSTRIES LIMITED (GB) | 1979-10-30 | — | — | US | disclosed |
| US-4115574-A | CNS ACTIVITY | LILLY INDUSTRIES LIMITED (GB) | 1978-09-19 | — | — | US | disclosed |
| US-4115568-A | CNS ACTIVITY | LILLY INDUSTRIES LIMITED (GB) | 1978-09-19 | — | — | US | disclosed |
| US-3984488-A | Dinitration of nitrobenzotrifluoride | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | PTGES, PTGS1, PTGIS | ALDH1A1 263/4885HIF1A 2178/4885VCAM1 2826/4885 |
| US-12485169-B2 | Compounds | SLC10A1, VHL, CFTR | ALDH1A1 276/4885HIF1A 1635/4885VCAM1 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.